Abstract:Poly (ADP-ribose) polymerases (PARP) are a family of nuclear protein enzymes involved in the DNA damage response. The role of PARP-1 in base excisional repair has been extensively characterized. More recent in vitro studies additionally implicate a role for PARP-1 in facilitating homologous recombination and nonhomologous end-joining. The more faithful process of homologous recombination repair of double-stranded DNA breaks involves localization of BRCA-1 and BRCA-2 to sites of DNA damage, resection of the double-stranded break, and gap-filling DNA synthesis using the homologous sister chromatid as a template. Simultaneous dysfunction of both DNA repair pathways decreases the ability of cells to compensate, and forms the basis for the concept of synthetic lethality. Treatment strategies, thus far, have focused on two main principles: (i) exploitation of the concept of synthetic lethality in homologous recombination-deficient tumors, primarily in breast and ovarian cancer patients with BRCA mutation, and (ii) as radiosensitizers and chemosensitizers. BRCA deficiency accounts for only a fraction of dysfunction in homologous recombination repair. Epigenetic alterations of BRCA function and defects within the Fanconi anemia pathway also result in defective DNA repair. Rational therapeutic combinations exploiting alternate mechanisms of defective DNA repair, abrogation of cell-cycle checkpoints, and additional functions of PARP-1 present novel opportunities for further clinical development of PARP inhibitors. On the basis of the results of clinical studies of PARP inhibitors thus far, it is imperative that future development of PARP inhibitors take a more refined approach, identifying the unique subset of patients that would most benefit from these agents, determining the optimal time for use, and identifying the optimal combination partner in any particular setting.

Regulation of PARP1/2 and the tankyrases: emerging parallels

Human PARP1 Substrates and Regulators of Its Catalytic Activity: an Updated Overview.

Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2

Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics

The expanding universe of PARP1-mediated molecular and therapeutic mechanisms

PARP1: Structural insights and pharmacological targets for inhibition

Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases

Poly‐ADP‐ribosylation dynamics, signaling, and analysis

Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions

ADP-ribosylation: from molecular mechanisms to human disease

The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions

Modulatory Potential of Poly (ADP‐Ribose) Polymerase 1 (PARP1) in BRCA‐Mutated Tumors

PARP inhibition: PARP1 and beyond

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Pleiotropic roles of tankyrase/PARP proteins in the establishment and maintenance of human naïve pluripotency

The dynamics and Regulation of PARP1 and PARP2 in response to DNA damage and during replication

DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy

Patents on PARP-1 Inhibitors for the Management of Cancer from 2017-2023

Molecular Pathways: Targeting PARP in Cancer Treatment

PARP enzymes and mono-ADP-ribosylation: advancing the connection from interferon-signalling to cancer biology

PARP Molecular Functions and Applications of PARP Inhibitors in Cancer Treatment